Related Experiment Video
Updated: Dec 2, 2025
A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
Published on: May 27, 2021
Synthetic Lethality through the Lens of Medicinal Chemistry
Samuel H Myers1, Jose Antonio Ortega1, Andrea Cavalli1,2
1Computational & Chemical Biology, Istituto Italiano di Tecnologia, 16163 Genova, Italy.
Abstract:
Personalized medicine and therapies represent the goal of modern medicine, as drug discovery strives to move away from one-cure-for-all and makes use of the various targets and biomarkers within differing disease areas. This approach, especially in oncology, is often undermined when the cells make use of alternative survival pathways. As such, acquired resistance is unfortunately common. In order to combat this phenomenon, synthetic lethality is being investigated, making use of existing genetic fragilities within the cancer cell. This Perspective highlights exciting targets within synthetic lethality, (PARP, ATR, ATM, DNA-PKcs, WEE1, CDK12, RAD51, RAD52, and PD-1) and discusses the medicinal chemistry programs being used to interrogate them, the challenges these programs face, and what the future holds for this promising field.
Insights
Synthetic lethality exploits cancer cell genetic weaknesses to create targeted therapies, overcoming drug resistance in personalized medicine. This approach investigates key targets like PARP and PD-1 for novel oncology treatments.
Area of Science:
- Oncology
- Genetics
- Pharmacology
Background:
- Personalized medicine aims to move beyond one-size-fits-all treatments.
- Acquired resistance to cancer therapies is a significant clinical challenge.
- Synthetic lethality offers a strategy to target cancer cells by exploiting their genetic vulnerabilities.
Purpose of the Study:
- To highlight key targets in synthetic lethality for cancer treatment.
- To discuss medicinal chemistry efforts targeting these synthetic lethal vulnerabilities.
- To explore the challenges and future directions in this field.
Main Methods:
- Review of current synthetic lethality targets (PARP, ATR, ATM, DNA-PKcs, WEE1, CDK12, RAD51, RAD52, PD-1).
- Discussion of medicinal chemistry programs and drug discovery approaches.
- Analysis of challenges and future prospects in synthetic lethality research.
Main Results:
- Identification of several promising synthetic lethality targets in oncology.
- Overview of ongoing medicinal chemistry efforts to develop inhibitors for these targets.
- Acknowledgement of challenges including target specificity and resistance mechanisms.
Conclusions:
- Synthetic lethality presents a promising avenue for developing novel cancer therapies.
- Targeting specific genetic fragilities offers a way to overcome acquired drug resistance.
- Continued research in medicinal chemistry is crucial for realizing the full potential of synthetic lethality.
Related Concept Videos
02:41Lethal Alleles
Lucien Cuénot discovered lethal alleles in 1905 while studying the inheritance of coat color in mice. The agouti gene is responsible for the color of the coat in mice. This gene codes for an agouti-signaling protein, which is responsible for melanin distribution in mammals. The wild-type allele gives rise to gray-brown coat color in mice, while the mutant allele gives rise to yellow coat color. In addition to coat color, the agouti gene is associated with the yellow...
01:27Combined Effects of Drugs: Synergism
Such synergistic combinations...
01:27Effects of Chemicals: Overview
02:55Synthetic Biology
Golden rice
Golden rice is a genetically modified...
01:16In-vitro Mutagenesis
01:17Antidotes
Specific antidotes operate by inhibiting the enzymes that control biochemical pathways, reducing the production of harmful metabolites.
An example of an antidote is atropine, which counteracts the detrimental effects of cholinesterase inhibitors. It achieves this by deactivating muscarinic receptors,...